Stocks · Health care · Biological Products, (No Diagnostic Substances)

Passage BIO, Inc.

PASG Clue Score25
United States Fiscal year ends December CIK 0001787297 Results filed 3 Mar 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Lynx1 Capital Management LP
25 Jun 2026
10% owner
Buy indirect
50,055
$4.12
$206.10K
Kathleen Borthwick
8 Jan 2026
CFO
Sold after exercise
2,062
$18.44
$38.02K
William Chou
8 Jan 2026
President and CEO
Sold after exercise
4,076
$18.44
$75.16K

What was left out

Form 4 filings counted 13
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 2
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 15,000
History held since 2 Mar 2020